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Over 50 Years of Fibrinogen Concentrate
Rubens Costa-Filho, MD, FCCP1, Gerald Hochleitner2,
Michael Wendt3, Alexandre Teruya, MD4, and
Donat R. Spahn, MD, FRCA5
Abstract
March 2013 represented the 50th anniversary of the first license granted for a fibrinogen concentrate. In this review, we look at
the history of bleeding management that led to the development of fibrinogen concentrate, discuss its current use, and consider
future developments for this product.
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Introduction
It is over 50 years since the first license for a fibrinogen
concentrate (FIBRINOGENIO HUMANO LIO.) was granted
in Brazil in 1963. Historically, fibrinogen came into focus
because of reports suggesting it was a cardiovascular risk fac-
tor, and there is still no final answer as to whether it is a med-
iator,1 or just a marker2 or predictor,3 of cardiovascular disease.
It is only recently that research started focusing on the positive
role of fibrinogen as a hemostatic agent, particularly in the
management of perioperative bleeding.
The History of the Term ‘‘Fibrinogen’’
Before we discuss the development of fibrinogen concentrate,
we take a historical look at where the term ‘‘fibrinogen’’ first
came from. As far back as the fifth- to fourth-century BC,
Hippocratic doctors noted the presence of fibers in circulating
blood. However, it was not until the end of the 17th century that
Malpighi, using a single lens microscope, observed that whole
blood clots have a fibrous and corpuscular component.4 The
term ‘‘fibrin’’ was introduced by Fourcroy in 1801. He demon-
strated that plasma contained soluble substances and that the
precursor of fibrin was present in plasma but not serum. A few
decades later, in 1847, the term ‘‘fibrinogen’’ was invented by
Virchow where he stated ‘‘should one want to give it a name, it
could be called fibrinogen’’ (translated from German: ‘‘viel-
mehr, wollte man sie benennen, so ko¨nnte man sie ho¨chstens
Fibrinogen taufen.’’).5(p.581) Some consider that he created the
term out of the words fibrin and oxygen, since he believed that
‘‘fibrin was a homogeneous mass formed from soluble fibrin
after exposure of blood or exudates to oxygen,’’6(p.301) and oth-
ers suggest that he composed the term by adding the syllable
‘‘ogen’’ for a precursor substance instead of the prefix ‘‘pro.’’
At the time, Virchow was experimenting with exudates, rather
than with whole blood, and therefore mistakenly applied the
term ‘‘fibrinogen’’ to decaying exudates rather than to the pre-
cursor of fibrin in whole blood as it was understood later. In
fact, Virchow had not discovered fibrinogen, instead Denis
(in his ‘‘Me´moire sur le sang’’ in 1859) was the first to recog-
nize that plasma contained a clottable substance different from
fibrin and went on to attempt to purify and characterize this
protein. Denis proposed the name fibrinogen (independent of
Virchow): ‘‘I believe that I should repeat once more that I do
not mean to define a liquid fibrin, plasma fibrin, but rather a
substance which is not at all fibrous and which is the origin
of fibrin, clottable lymph, a substance which I would like to call
‘se´rofibrine’ and which one might also designate by the name
‘fibrinoge`ne’, if such a word would be admissible.’’7 Neverthe-
less, it took a further 20 years before fibrinogen was first iso-
lated by Hammarsten (1879) who precipitated and purified it
from horse plasma by salting-out with sodium chloride in what
has become the classical procedure for fibrinogen preparation.6
The History of Bleeding Management
Nowadays, bleeding management encompasses, among other
things, the assessment of bleeding risk prior to surgery, and
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monitoring and managing blood loss during surgery, including
appropriate management of bleeding. Historically, the develop-
ment of therapeutic blood management can be traced back to
the 17th century where the first animal-to-human blood trans-
fusion was conducted in 1667.8 However, it was not until
1818 that James Blundell, a British obstetrician, performed
the first human-to-human transfusion—to save a patient from
exsanguination.9 The introduction of blood transfusion into
the medical armamentarium was further advanced with the
groundbreaking discovery of the ABO blood group by the
Austrian–American immunologist and pathologist Karl Land-
steiner in 1901, a feat for which he was later awarded the
Nobel Prize.10
Over the last 100 years, further developments have served to
transform the practice of transfusion medicine.11 One of the
most relevant developments is the shift from using whole blood
to using specific blood components (e.g., red blood cells, plate-
lets, and fresh frozen plasma [FFP]) and further to the purified,
virus-inactivated, plasma-derived products (such as factor con-
centrates). This latter development was made possible by the
work of Edwin Joseph Cohn who discovered that the complex
mixture of components in whole blood could be separated
through a process of fractionation, commonly referred to as
‘‘Cohn fractionation.’’12 In 1947, he described 6 major plasma
fractions, with fraction I containing most of the fibrinogen.
Cohn emphasized the importance of separating different
plasma components, as it was more efficient and less wasteful
to use a particular component for a specific need rather than
whole plasma. This approach proved of great value during
World War II with the development of products such as fibrin
foam helping to solve major problems connected with hemos-
tasis. This change from the use of specific blood components to
purified plasma-derived products for bleeding management
represents a continuing paradigm shift.
Fibrinogen Concentrate: The Past and
The Present
Duringmajor bleeding and replacement with red blood cell con-
centrates, fibrinogen is the first clotting factor to reach critically
low levels.13 Furthermore, low perioperative fibrinogen levels
have been shown to be associated with increased bleeding.14
Therefore, increasing the levels through fibrinogen supplemen-
tation appears essential to restore normal clotting function.15-17
The standard practice of replacing fibrinogen has focused on
infusions of therapeutic plasma (eg, FFP) or cryoprecipitate;
however, there are differences concerning the volume of each
product.18 Furthermore, there are various well-known disadvan-
tages of using these products.11,19 Some of the issues are related
to the safety and purity of these products. Therefore, with the
progression from using whole blood to allogeneic blood prod-
ucts (eg, plasma, red blood cells, platelet concentrates, and cryo-
precipitate), the next consideration should be moving toward
more purified, specific products such as factor concentrates
(eg, fibrinogen concentrate). This represents the move from the
use of a ‘‘liquid organ’’ to a pharmaceutical product.
Fibrinogen concentrate (FIBRINOGENIO HUMANO LIO.)
was first approved for use in Brazil on March 4, 1963. This day
is considered the international birth date of the product. Nota-
bly, fibrinogen concentrate and freeze-dried fraction I (pre-
pared by Cohn fractionation of plasma) were already
available before licensure of this product became obliga-
tory.20-22 The European Union birth date of the product is Jan-
uary 4, 1966,23 when fibrinogen concentrate (Human-
Fibrinogen Behringwerke Konzentrat) was approved in Europe
for the first time by the German Federal Ministry of Health.
However, Behringwerke (a predecessor company of CSL Behr-
ing GmbH) had already commenced production of human fibri-
nogen concentrate in 1956, before registration of a product
became mandatory with the Medicinal Products Act coming
in to force in 1961 in Germany. In 1985, the production process
was modified to include pasteurization as a virus inactivation
step, and the product was renamed Haemocomplettan P (CSL
Behring GmbH). Currently, all formulations of fibrinogen con-
centrate manufactured by CSL Behring are pasteurized, and
over 3 million grams have been used since 1985.24
At the time of writing, CSL Behring’s fibrinogen concen-
trate is approved for treatment and prophylaxis of acquired
and congenital fibrinogen deficiency under the trade name
Haemocomplettan P in several countries (Table 1).25,26 In
Israel, Haemocomplettan P is indicated for the treatment
of acute bleeding episodes in patients with congenital fibri-
nogen deficiency, including afibrinogenemia and hypofibri-
nogenemia. The same product, licensed under the trade
name RiaSTAP, is also available for the treatment of acute
bleeding episodes in patients with congenital fibrinogen
deficiency, including afibrinogenemia and hypofibrinogen-
emia, in Australia, Canada, Mexico, New Zealand, Puerto
Rico, United States, and several European countries
(Table 1).25,26
Current evidence suggests that fibrinogen concentrate has a
good safety profile and delivers a standardized dose of fibrino-
gen.27 Haemocomplettan P/RiaSTAP has been shown to be
effective and well tolerated in a number of clinical studies of
patients with congenital or acquired fibrinogen deficiency.28-35
A postmarketing surveillance study of Haemocomplettan
P/RiaSTAP covering a 27-year period (1986-2013) found
28 spontaneous reports of possibly related thrombotic events
for 2 611 294 g of distributed product.27 This represents an
incidence rate of 1 event per 23 300 doses.
The use of Haemocomplettan P/RiaSTAP to control bleed-
ing and to decrease the use of allogeneic blood products during
cases of acquired bleeding has been reported in a variety of
clinical settings, including surgery, trauma, liver transplanta-
tion, and obstetrics.28-30,33,36-43 Furthermore, recent systematic
reviews confirm that the use of fibrinogen concentrate may
reduce allogeneic blood product transfusion44-46; however,
very often the trials are of low quality with a high risk of bias.
Moreover, the measured outcomes, such as transfusion require-
ments, may be prone to performance bias.47 Therefore, more
randomized controlled trials are warranted before it can be con-
firmed whether fibrinogen concentrate has a definitive role in
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the management of bleeding. Additionally, some controversy
still exists around the use of fibrinogen concentrate with regard
to the appropriate level of fibrinogen to trigger treatment.48,49
Ranucci and Solomon are right to note in their Editorial that
there is currently a discrepancy among licences, guidelines, and
clinical use and that there are open issues and gaps in knowl-
edge that need to be addressed.50
What Does the Future Hold for
Fibrinogen Concentrate?
Four fibrinogen concentrate products are currently available in
various regions25 and according to public sources more are in
development.51 Other developments include the production
of recombinant fibrinogen, first engineered by Lord et al in
Table 1. Current Licensing Status of Fibrinogen Concentrate Manufactured by CSL Behring.
Product Name Availabilitya Date of First Approval Indication
Haemocomplettan1 Pb Argentina August 2012 Treatment and prophylaxis of acquired and congenital fibrinogen
deficiencyAustria June 1994
Brazil March 1963 (March 2008c)
Bulgaria January 2009
Czech Republic March 1993
Germany March 1966 (March 2005c)
Hungary June 1998
Iran January 2010
Kuwait October 2003
Lebanon December 2013
Netherlands March 1997
Portugal January 1978
Romania July 1999
Switzerland November 1992
Taiwan March 1970 (January 1987c)
Tunisia April 2013
Turkey October 1997
Uruguay October 2013
Israel August 2009 Treatment of acute bleeding episodes in patients with congenital
fibrinogen deficiency, including afibrinogenemia and
hypofibrinogenemia
RiaSTAP1 Australia August 2010 Treatment of acute bleeding episodes in patients with congenital
fibrinogen deficiency, including afibrinogenemia and
hypofibrinogenemia
Belgium October 2010
Canada September 2012
Cyprus January 2012
Denmark August 2010
Finland September 2010
France October 2010
Germany December 2009
Greece May 2011
Iceland August 2010
Ireland September 2010
Italy April 2012
Luxembourg February 2011
Malta February 2012
Mexico January 2013
New Zealand May 2011
Norway November 2010
Poland June 2011
Puerto Rico December 2009
Slovakia October 2010
Slovenia June 2011
Spain March 2011
Sweden October 2010
United Kingdom August 2010
United States January 2009
aAdditional countries received licenses to use the product that are no longer active, for example, pre-1985 (Colombia, Jamaica, Pakistan) and post-1985 (Croatia, India).
bOther trade names have been used for this product during the licensing history and in other countries, for example, FIBRINOGENIO HUMANO LIOF, Fibri-
nogenio Humano, Fibrinogenio, Haemocomplettan, Haemocomplettan HS, Human-Fibrinogen Behringwerke Konzentrat.
cApproval date of current license.
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1993.52 The functional properties of a recombinant fibrinogen
have been tested ex vivo in whole blood samples from a group
of patients undergoing cardiac surgery.53 According to the
clinical trials registries (clinicaltrials.gov and clinicaltrialsre-
gister.eu), there are currently 11 ongoing clinical studies
investigating the use of fibrinogen concentrate in acquired
bleeding. The results of these studies will potentially provide
further evidence on the role of fibrinogen concentrate in the
management of bleeding.
These ongoing investigations will provide additional evi-
dence of fibrinogen concentrate in acquired bleeding, but fibri-
nogen may have a number of different applications beyond
bleeding management. Thrombocytopenia is a common compli-
cation in hospitalized patients which affects blood clotting, and
studies have shown that fibrinogen concentrate can increase the
clot strength, independent of platelet count.54,55 Further clinical
investigations are necessary to confirm whether bleeding com-
plications associated with thrombocytopenia could be managed
through supplementation with fibrinogen concentrate. The role
of fibrinogen and interference with the immune system is also
worthy of further scrutiny, as a significant decrease in sepsis-
induced mortality was observed in animals treated with fibrino-
gen concentrate in a rat model of sepsis-induced disseminated
intravascular coagulation.56
Advances in science and medicine have led to improvements
in blood and blood products and in the way patients are treated.
Fibrinogen concentrate seems to offer a specific option in the
management of bleeding; however, further investigations are
required to clearly define its role. Fibrinogen concentrate was
described in 2009 as a ‘‘potential universal hemostatic agent’’57;
the next 50 years will demonstrate whether this is the case.
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